Il y a eu 50 transactions d'initiés récentes enregistrées pour Ventyx Biosciences, Inc. (VTYX), dont 24 achats et 24 ventes. Le total des achats d'initiés s'élève à $7M et le total des ventes d'initiés à $2.56M.
Les initiés notables ayant une activité récente comprennent Subramaniam Somu, Hulme Allison, Gujrathi Sheila. Les transactions d'initiés peuvent fournir des indications sur la façon dont la direction perçoit la valorisation et les perspectives futures de l'action.
Transactions d'Initiés — VTYX
| Date |
Nom |
Rôle |
Type de Transaction |
Actions |
Prix Moyen |
Valeur |
Actions détenues |
| 2025-06-05 |
Subramaniam Somu |
Director |
Attribution de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Hulme Allison |
Director |
Attribution de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Gujrathi Sheila |
Director |
Attribution de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
White William Richard |
Director |
Attribution de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-06-05 |
Cadoret-manier Onaiza |
Director |
Attribution de RSU |
40,000 |
$2.25 |
$90K |
40,000 |
| 2025-05-15 |
Forman Mark S |
Chief Medical Officer |
Attribution de RSU |
3,000 |
$1.03 |
$3.09K |
3,000 |
| 2025-05-15 |
Gonzales Roy |
Senior VP, Finance |
Attribution de RSU |
1,750 |
$1.03 |
$1.8K |
3,546 |
| 2025-04-02 |
Nuss John |
Chief Scientific Officer |
Vente Informative |
1,887 |
$1.07 |
$2.02K |
467,226 |
| 2025-03-28 |
Subramaniam Somu |
Director |
Autre (Vente) |
1,335,450 |
- |
- |
4,032,213 |
| 2025-03-28 |
Nuss John |
Chief Scientific Officer |
Exercice d'Options (Vente) |
4,531 |
- |
- |
9,063 |
| 2025-03-28 |
Mohan Raju |
CEO and President |
Exercice d'Options (Vente) |
11,844 |
- |
- |
23,688 |
| 2025-03-10 |
Subramaniam Somu |
Director |
Autre (Vente) |
1,735,306 |
- |
- |
5,367,663 |
| 2025-01-02 |
Moore Matthew Richard |
Chief Operating Officer |
Attribution de RSU |
145,000 |
$2.14 |
$310.3K |
145,000 |
| 2025-01-02 |
Nuss John |
Chief Scientific Officer |
Attribution de RSU |
170,104 |
$2.14 |
$364.02K |
170,104 |
| 2025-01-02 |
Mohan Raju |
CEO and President |
Attribution de RSU |
700,000 |
$2.14 |
$1.5M |
700,000 |
| 2025-01-02 |
Forman Mark S |
Chief Medical Officer |
Attribution de RSU |
85,000 |
$2.14 |
$181.9K |
85,000 |
| 2025-01-02 |
Gonzales Roy |
Senior VP, Finance |
Attribution de RSU |
17,500 |
$2.14 |
$37.45K |
17,500 |
| 2024-12-27 |
Nuss John |
Chief Scientific Officer |
Vente Informative |
21,119 |
$2.36 |
$49.84K |
464,582 |
| 2024-12-23 |
Gujrathi Sheila |
Director |
Achat Informatif |
130,000 |
$2.31 |
$300.57K |
130,000 |
| 2024-12-19 |
Nuss John |
Chief Scientific Officer |
Vente Informative |
13,161 |
$2.26 |
$29.68K |
485,701 |
| 2024-12-17 |
Nuss John |
Chief Scientific Officer |
Exercice d'Options (Vente) |
34,930 |
- |
- |
34,930 |
| 2024-12-17 |
Mohan Raju |
CEO and President |
Exercice d'Options (Vente) |
116,668 |
- |
- |
116,668 |
| 2024-12-10 |
Nuss John |
Chief Scientific Officer |
Exercice d'Options (Vente) |
193,557 |
$0.20 |
$38.71K |
- |
| 2024-11-25 |
Mohan Raju |
CEO and President |
Achat Informatif |
261,752 |
$2.01 |
$524.94K |
2,175,028 |
| 2024-11-22 |
Mohan Raju |
CEO and President |
Achat Informatif |
238,248 |
$1.83 |
$434.95K |
1,913,276 |
| 2024-08-30 |
Gonzales Roy |
Senior VP, Finance |
Cession |
70,000 |
$33.84 |
$2.37M |
- |
| 2024-08-12 |
Forman Mark S |
Officer |
Inconnu |
- |
- |
- |
- |
| 2024-08-12 |
Forman Mark S |
Chief Medical Officer |
Attribution de RSU |
350,000 |
$1.95 |
$682.5K |
350,000 |
| 2024-06-24 |
Subramaniam Somu |
10 Percent Owner |
Autre (Vente) |
641,327 |
- |
- |
7,102,969 |
| 2024-06-24 |
Nsv Partners Iii Lp |
10 Percent Owner |
Autre (Vente) |
641,327 |
- |
- |
7,102,969 |
| 2024-06-10 |
Mohan Raju |
CEO and President |
Exercice d'Options (Vente) |
96,778 |
$0.20 |
$19.36K |
- |
| 2024-06-06 |
Subramaniam Somu |
10 Percent Owner |
Attribution de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Hulme Allison |
Director |
Attribution de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Gujrathi Sheila |
Director |
Attribution de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
White William Richard |
Director |
Attribution de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-06-06 |
Cadoret-manier Onaiza |
Director |
Attribution de RSU |
33,000 |
$3.29 |
$108.41K |
33,000 |
| 2024-05-16 |
Moore Matthew Richard |
Officer |
Inconnu |
- |
- |
- |
- |
| 2024-05-16 |
Moore Matthew Richard |
Chief Operating Officer |
Attribution de RSU |
320,000 |
$4.98 |
$1.59M |
320,000 |
| 2024-04-12 |
Subramaniam Somu |
10 Percent Owner |
Autre (Vente) |
695,339 |
- |
- |
7,744,296 |
| 2024-04-12 |
Nsv Partners Iii Lp |
10 Percent Owner |
Autre (Vente) |
695,339 |
- |
- |
7,744,296 |
| 2024-04-02 |
Krueger Christopher W |
Chief Business Officer |
Vente Informative |
1,651 |
$5.40 |
$8.92K |
284,999 |
| 2024-04-02 |
Nuss John |
Chief Scientific Officer |
Vente Informative |
1,651 |
$5.40 |
$8.92K |
264,998 |
| 2024-04-02 |
Auster Martin |
Chief Financial Officer |
Vente Informative |
1,405 |
$5.40 |
$7.59K |
24,303 |
| 2024-04-02 |
Mohan Raju |
CEO and President |
Vente Informative |
4,312 |
$5.40 |
$23.3K |
1,578,250 |
| 2024-03-28 |
Krueger Christopher W |
Chief Business Officer |
Exercice d'Options (Vente) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Nuss John |
Chief Scientific Officer |
Exercice d'Options (Vente) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Auster Martin |
Chief Financial Officer |
Exercice d'Options (Vente) |
4,531 |
- |
- |
13,594 |
| 2024-03-28 |
Mohan Raju |
CEO and President |
Exercice d'Options (Vente) |
11,843 |
- |
- |
35,532 |
| 2024-01-21 |
Subramaniam Somu |
10 Percent Owner |
Attribution de RSU |
20,000 |
$1.97 |
$39.4K |
20,000 |
| 2024-01-21 |
Hulme Allison |
Director |
Attribution de RSU |
20,000 |
$1.97 |
$39.4K |
20,000 |
■ Informatif — transaction sur marché ouvert (la plus significative)
■ Non informatif (achat) — récompense, exercice d'option, conversion
■ Non informatif (vente) — retenue fiscale, vente à l'acquisition
■ Neutre — don, fiducie, expiration
Les autres consultent aussi
